STOCK TITAN

Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Theratechnologies Inc. to report Q3 financial results on September 26, 2023
Positive
  • None.
Negative
  • None.

MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.

The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access.

Conference call dial-in and replay information is below:

CONFERENCE CALL INFORMATION
Conference Call DateSeptember 26, 2023
Conference Call Time8:30 a.m. EDT
Webcast linkhttps://edge.media-server.com/mmc/p/3ghrwkyd
Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)
Access Code9250897

An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.

Contacts:

Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
ir@theratech.com
438-315-6608


Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

59.77M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.